MedTrace Logo

A Study of Patients With Fabry Disease (US Specific)

NCT06906367 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2026-05-18

No results posted yet for this study

Summary

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

Conditions

Interventions

DRUG

migalastat HCl

Non-interventional study of participants receiving migalastat HCl 150 mg

DRUG

ERT

Non-interventional study of participants receiving enzyme replacement therapy

Sponsors & Collaborators

  • Amicus Therapeutics

    lead INDUSTRY

Principal Investigators

  • Clinical Research · Amicus Therapeutics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-13
Primary Completion
2032-06-30
Completion
2032-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06906367 on ClinicalTrials.gov